RESULTS OF CHEMOTHERAPY PACLITAXEL- CARBOPLATIN TREATMENT IN METASTATIC THYMIC CARCINOMA AT K HOSPITAL
Tóm tắt
.
Abstract
Abstract:
Objective: Evaluation of clinical and paraclinical characteristics and treatment results of Paclitaxel-Carboplatin in metastatic thymic carcinoma at K Hospital.
Subjects and Methods: A retrospective study with longitudinal follow-up on patients diagnosed with metastatic thymic carcinoma (AJCC 8th edition), treated with the Paclitaxel-Carboplatin chemotherapy regimen from 2020 to 2024 at K Hospital.
Results: The study included 20 patients with an average age of 56.4 years; 65% were male and 35% were female. ECOG 0 accounted for 70% and ECOG 1 for 30%. The predominant histological type was squamous cell carcinoma (70%). The treatment results showed a response rate of 45% and a disease control rate (DCR) of 75%. The median progression-free survival (mPFS) was 8.7 months after a follow-up of 15.6 months. Hematologic toxicity related to the regimen included anemia in 55% of patients (grade 3 in 5%) and neutropenia in 55% (grade 3 in 10%). Non-hematologic toxicity was commonly observed in the peripheral nervous system (40%) and elevated AST/ALT levels (45%), mainly grades 1 and 2.
Conclusion: The combination of paclitaxel and carboplatin is an effective treatment option for metastatic thymic carcinoma in patients who have not previously received systemic therapy
Từ khóa
.
Keywords
Keywords: Thymic carcinoma; Metastasis; Paclitaxel-Carboplatin.
Tài liệu tham khảo (References)
- Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years’ experience in twenty patients. J Thorac Cardiovasc Surg. 1994;107(2):615-620.
- Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67(4):1025-1032. doi:10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f
- Wick MR, Scheithauer BW, Weiland LH, Bernatz PE. Primary thymic carcinomas. Am J Surg Pathol. 1982;6(7):613-630. doi:10.1097/00000478-198210000-00003
- Liu HC, Hsu WH, Chen YJ, et al. Primary thymic carcinoma. Ann Thorac Surg. 2002;73(4):1076-1081. doi:10.1016/s0003-4975(01)03607-4
- Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol. 2002;25(3):266-268. doi:10.1097/00000421-200206000-00012
- Yoh K, Goto K, Ishii G ichiro, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 2003;98(5):926-931. doi:10.1002/cncr.11606
- Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26(2):363-368. doi:10.1093/annonc/mdu541
- Song Z. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. Journal of Thoracic Disease. 2014;6(12). doi:10.3978/j.issn.2072-1439.2014.11.18
- Lemma GL, Lee JW, Aisner SC, et al. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma. J Clin Oncol. 2011;29(15):2060-2065. doi:10.1200/JCO.2010.32.9607
- Loehrer PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12(6):1164-1168. doi:10.1200/JCO.1994.12.6.1164
